Related Experiment Video
Updated: Aug 14, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
CLL biology and prognosis
1Institute Pasteur, 28 Rue du Dr. Roux, Paris 75724, France. dighiero@pasteur.fr
Hematology. American Society of Hematology. Education Program
|November 24, 2005
Summary
Chronic lymphocytic leukemia (CLL) prognosis is variable. Recent advances in molecular markers like Ig gene mutational profiles offer better prediction, prompting new questions about CLL biology and staging.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Chronic lymphocytic leukemia (CLL) exhibits highly variable clinical courses.
- Advances in identifying molecular and cellular markers are improving prognostic accuracy.
- Ig gene mutational profiles and cytogenetic abnormalities are key prognostic indicators.
Purpose of the Study:
- To address critical questions regarding CLL biology and prognosis.
- To explore the role of the B-cell receptor (BCR) in CLL pathogenesis.
- To evaluate the utility of current staging systems and identify surrogates for Ig mutational profiles.
Main Methods:
- Review and synthesis of recent research findings in CLL.
- Analysis of molecular markers, including Ig gene mutational status.
- Evaluation of prognostic factors and staging systems.
Main Results:
- Ig gene mutational profiles and cytogenetic abnormalities significantly impact CLL prognosis.
- The B-cell receptor (BCR) plays a crucial role in CLL pathogenesis.
- Existing staging systems may require re-evaluation in light of new molecular data.
Conclusions:
- Understanding CLL pathogenesis requires further investigation into BCR signaling and B-cell origins.
- New molecular markers offer superior prognostic value compared to traditional staging.
- CLL may represent a spectrum of disease rather than a single entity.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...